Regulatory requirements and approval procedures for New Drugs

Definition of New Drugs

• Under the Drugs and Cosmetics Act, a “new drug” is:
  • A drug not previously used in India.
  • A previously approved drug proposed with new claims.
  • A fixed-dose combination of drugs not previously approved.

Steps in New Drug Approval

1. Pre-Clinical Studies

   • Objective: Assess safety and efficacy through lab and animal studies.
   • Studies Conducted: Pharmacodynamics, pharmacokinetics, toxicology, reproductive, genotoxicity, and carcinogenicity.
   • Compliance: Must follow Good Laboratory Practices (GLP).

2. Investigational New Drug (IND) Application

   • Purpose: Seek approval for human trials.
   • Submission Includes: Pre-clinical data, clinical trial protocols, and an investigator’s brochure.

3. Clinical Trials

   • Conducted in phases under the New Drugs and Clinical Trials Rules, 2019.
   • Phase I: Small group of healthy volunteers to assess safety.
   • Phase II: 100-300 patients to evaluate efficacy and side effects.
   • Phase III: 1,000-3,000 patients for efficacy and safety.
   • Phase IV: Post-marketing surveillance for long-term safety.

4. New Drug Application (NDA) Submission

   • Purpose: Approval to market the drug.
   • Contents: Administrative details, data summaries, quality data, study reports, and labeling information.

5. CDSCO Review Process

   • Screening: Initial application completeness check.
   • Expert Evaluation: Subject Expert Committees (SECs) review data; Technical Committee provides recommendations.
   • Approval Decision: CDSCO grants permission if data is satisfactory, with conditions for post-marketing requirements as needed.

6. Post-Approval Requirements

   • Pharmacovigilance: Adverse drug reaction reporting and periodic safety updates.
   • Compliance: Additional studies and labeling updates as needed.

Special Considerations

• Fast-Track Approvals: Available for drugs addressing unmet medical needs.
• Global Clinical Trials: Requires ethics committee approval and regulatory permissions.

Regulatory Framework

• New Drugs and Clinical Trials Rules, 2019: Governs approvals, ethical considerations, and trial conduct.
• Ethical Guidelines: Compliance with Good Clinical Practices (GCP) and informed consent is mandatory.
• Intellectual Property: Patent status may influence market exclusivity and generic competition.

Click Here to Watch the Best Pharma Videos